|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM329439588 |
| 003 |
DE-627 |
| 005 |
20240222231852.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108823
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1302.xml
|
| 035 |
|
|
|a (DE-627)NLM329439588
|
| 035 |
|
|
|a (NLM)34400321
|
| 035 |
|
|
|a (PII)S1521-6616(21)00160-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zanin-Zhorov, Alexandra
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.09.2021
|
| 500 |
|
|
|a Date Revised 22.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Chronic graft-versus-host disease (cGVHD) is an immune-mediated disorder characterized by chronic inflammation and fibrosis. Rho-associated coiled-coil-containing protein kinases (ROCKs) are key coordinators of tissue response to injury, regulating multiple functions, such as gene expression and cell migration, proliferation and survival. Relevant to cGVHD and autoimmunity, only the ROCK2 isoform drives a pro-inflammatory type 17 helper T (Th17) cell response. Moreover, ROCK2 inhibition shifts the Th17/regulatory T (Treg) cell balance toward Treg cells and restores immune homeostasis in animal models of autoimmunity and cGVHD. Furthermore, the selective inhibition of ROCK2 by belumosudil reduces fibrosis by downregulating both transforming growth factor-β signaling and profibrotic gene expression, thereby impeding the creation of focal adhesions. Consistent with its anti-inflammatory and antifibrotic activities, belumosudil has demonstrated efficacy in clinical studies, resulting in an overall response rate of >70% in patients with cGVHD who failed 2 to 5 prior lines of systemic therapy. In summary, selective ROCK2 inhibition has emerged as a promising novel therapeutic approach for treating cGVHD and other immunologic diseases with unique mechanisms of action, targeting both immune imbalance and detrimental fibrotic responses
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Belumosudil
|
| 650 |
|
4 |
|a Chronic graft-versus-host disease
|
| 650 |
|
4 |
|a Fibrosis
|
| 650 |
|
4 |
|a Immunomodulation
|
| 650 |
|
4 |
|a ROCK2
|
| 650 |
|
7 |
|a Acetamides
|2 NLM
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a belumosudil
|2 NLM
|
| 650 |
|
7 |
|a ROCK1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a ROCK2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a rho-Associated Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 700 |
1 |
|
|a Blazar, Bruce R
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 230(2021) vom: 08. Sept., Seite 108823
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:230
|g year:2021
|g day:08
|g month:09
|g pages:108823
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108823
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 230
|j 2021
|b 08
|c 09
|h 108823
|